Form 4: RxSight COO Granted 32,218 Restricted Stock Units

RxSight, Inc. Chief Operating Officer Ilya Goldshleger received a grant of 32,218 restricted stock units, vesting over several years.

Summary

• Ilya Goldshleger, Chief Operating Officer of RxSight, Inc. (RXST), was granted 32,218 Restricted Stock Units (RSUs) on February 27, 2026.
• Each RSU represents a contingent right to receive one share of RxSight's Common Stock.
• The RSUs will vest in six equal installments, with the first vesting on or after August 31, 2026, and subsequent vestings occurring semi-annually until February 28, 2029.
• Vesting is contingent upon Mr. Goldshleger's continued service as a Service Provider to the company, as defined in the Issuer's 2021 Equity Incentive Plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine executive compensation event, slightly positive as it reinforces executive alignment with shareholder interests, but not significantly impacting the company's immediate operational or financial outlook.

Positives

• The RSU grant aligns the Chief Operating Officer's long-term interests with those of shareholders, incentivizing continued performance and retention.
• This compensation structure is a common practice for executive retention and motivation in publicly traded companies.

Negatives

• The vesting of these RSUs will result in future dilution for existing shareholders as new shares are issued.

Risks

• The value of the RSUs is tied to the future performance of RxSight's common stock, meaning the actual value realized by the COO could be lower than the current market value if the stock price declines.
• The company faces the risk of losing a key executive if the vesting conditions are not met or if Mr. Goldshleger leaves the company before the RSUs fully vest.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that granting restricted stock units to key executives like a Chief Operating Officer is a standard practice across the biotechnology and medical device industries. This method of compensation is widely used to attract, retain, and incentivize top talent by aligning their long-term financial interests with the company's performance and shareholder value creation.

Comparison to Industry Standards

• The RSU grant to RxSight's COO is consistent with executive compensation practices observed in comparable medical technology companies.
• Companies such as Alcon (ALC), Bausch + Lomb (BLCO), and Johnson & Johnson (JNJ) frequently utilize similar long-term equity incentives to retain key personnel and foster long-term growth.
• The multi-year vesting schedule is typical for such grants, aiming to ensure sustained executive commitment over several fiscal periods.

Corporate Governance

Related Party Transactions

• The grant of 32,218 Restricted Stock Units to Ilya Goldshleger, the Chief Operating Officer, constitutes a related party transaction as it involves compensation between the company and a key executive.

Stakeholder Impact

• Shareholders: Potential future dilution upon RSU vesting; increased alignment of executive incentives with long-term shareholder value.
• Employees: May signal stability in executive leadership and a commitment to long-term incentive programs.
• Ilya Goldshleger (COO): Receives a significant equity award, providing a long-term incentive and potential for wealth creation tied to company performance.

Next Steps

• Continued service of Ilya Goldshleger as a Service Provider to meet vesting conditions.
• Future vesting events for the RSUs on the specified semi-annual dates through February 28, 2029.

Key Dates

Keywords

RxSight, RXST, Ilya Goldshleger, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Form 4, Equity Grant, Corporate Governance